{"url_path":"/sec/kytx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-219397-index.html","accession_number":"0001193125-26-219397","cik":"0001994702","ticker":"KYTX","issuer_name":"Kyverna Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1994702/0001193125-26-219397-index.html","primary_entity_key":"0001994702","primary_entity_name":"Kyverna Therapeutics, Inc."},"word_count":333,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of Kyverna Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 12, 2024)](https://www.sec.gov/Archives/edgar/data/1994702/000119312524032161/d765670dex31.htm).\n\n3.2\n\n \n\n[Amended and Restated Bylaws of Kyverna Therapeutics, Inc. (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 12, 2024)](https://www.sec.gov/Archives/edgar/data/1994702/000119312524032161/d765670dex32.htm).\n\n4.1\n\n \n\n[Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-276523) filed with the SEC on January 16, 2024)](https://www.sec.gov/Archives/edgar/data/1994702/000119312524008614/d530411dex41.htm).\n\n10.1*#\n\n \n\n[Employment Offer Letter, dated January 13, 2026, between Kyverna Therapeutics, Inc. and Mayo Pujols.](kytx-ex10_1.htm)\n\n31.1*\n\n \n\n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934.](kytx-ex31_1.htm)\n\n31.2*\n\n \n\n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934.](kytx-ex31_2.htm)\n\n32.1**\n\n \n\n[Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](kytx-ex32_1.htm)\n\n32.2**\n\n \n\n[Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](kytx-ex32_2.htm)\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n* Filed herewith.\n\n** Furnished herewith.\n\n# Indicates management contract or compensatory plan or arrangement.\n\n \n\n \n\n102\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nKYVERNA THERAPEUTICS, INC.\n\nDate: May 12, 2026\n\nBy:\n\n/s/ Warner Biddle\n\nWarner Biddle\n\nChief Executive Officer\n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 12, 2026\n\n \n\nBy:\n\n/s/ Marc Grasso\n\n \n\n \n\n \n\nMarc Grasso\n\n \n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n103"}